Insmed, Inc. (INSM)
| Market Cap | 3.42B |
| Revenue (ttm) | 173.75M |
| Net Income (ttm) | -423.89M |
| Shares Out | 118.37M |
| EPS (ttm) | -3.92 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 627,401 |
| Open | 30.57 |
| Previous Close | 30.61 |
| Day's Range | 28.29 - 30.46 |
| 52-Week Range | 22.00 - 45.44 |
| Beta | 2.17 |
| Analysts | Strong Buy |
| Price Target | 53.44 (+84.7%) |
| Earnings Date | Oct 28, 2021 |
About INSM
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a tr...
Financial Performance
In 2020, Insmed's revenue was $164.41 million, an increase of 20.48% compared to the previous year's $136.47 million. Losses were -$294.09 million, 15.6% more than in 2019.
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for Insmed stock is "Strong Buy." The 12-month stock price forecast is 53.44, which is an increase of 84.72% from the latest price.
News
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BRIDGEWATER, N.J., Nov. 5, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, toda...
Insmed To Participate in Three November Conferences
BRIDGEWATER, N.J., Nov. 3, 2021 /PRNewswire/ -- Insmed Incorporated Inc. (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases...
New Strong Sell Stocks for October 29th
IBIO, POST, INSM, DVA, and BSET have been added to the Zacks Rank #5 (Strong Sell) List on October 29, 2021.
Insmed (INSM) Reports Q3 Loss, Lags Revenue Estimates
Insmed (INSM) delivered earnings and revenue surprises of -15.66% and -2.77%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Insmed (INSM) to Report a Decline in Earnings: What to Look Out for
Insmed (INSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Insmed to Host Third Quarter 2021 Financial Results Conference Call on Thursday, October 28, 2021
BRIDGEWATER, N.J., Oct. 14, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, tod...
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BRIDGEWATER, N.J., Oct. 5, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, toda...
Insmed To Participate in Five September Conferences
BRIDGEWATER, N.J., Sept. 1, 2021 /PRNewswire/ -- Insmed Incorporated Inc. (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare disease...
Insmed (INSM) Sees Hammer Chart Pattern: Time to Buy?
Insmed (INSM) has been struggling lately, but the selling pressure may be coming to an end soon.
Insmed (INSM) Reports Q2 Loss, Tops Revenue Estimates
Insmed (INSM) delivered earnings and revenue surprises of -10.59% and 4.46%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Insmed Reports Second Quarter 2021 Financial Results and Provides Business Update
BRIDGEWATER, N.J., Aug. 5, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, toda...
Earnings Preview: Insmed (INSM) Q2 Earnings Expected to Decline
Insmed (INSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why Insmed (INSM) is Poised for a Turnaround After Losing 19.5% in 4 Weeks
Insmed (INSM) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates coul...
Insmed to Host Second Quarter 2021 Financial Results Conference Call on Thursday, August 5, 2021
BRIDGEWATER, N.J., July 27, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, tod...
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BRIDGEWATER, N.J., July 8, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, toda...
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BRIDGEWATER, N.J., June 4, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, toda...
Insmed To Present at Two June Conferences
BRIDGEWATER, N.J., May 25, 2021 /PRNewswire/ -- Insmed Incorporated Inc. (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases...
Insmed Presents Broad Range of Data Across Its Three Programs at the American Thoracic Society 2021 International Con...
BRIDGEWATER, N.J., May 19, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, toda...
Insmed Announces Closing of Public Offerings of Common Stock and Convertible Senior Notes and Full Exercise of Underw...
BRIDGEWATER, N.J., May 13, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM) announced today the closing of the previously announced registered underwritten public offering (the "Equity Offering")...
Insmed Announces Pricing of Concurrent Public Offerings of Common Stock and Convertible Senior Notes due 2028
BRIDGEWATER, N.J., May 11, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM) announced today that it priced a registered underwritten public offering of 10,000,000 shares of its common stock (the ...
Insmed Announces Proposed Concurrent Public Offerings of Common Stock and Convertible Senior Notes due 2028
BRIDGEWATER, N.J., May 10, 2021 /PRNewswire/ — Insmed Incorporated (Nasdaq: INSM) announced today that it intends to offer and sell $250 million of its common stock (the "Shares") and $500 million aggre...
Insmed (INSM) Reports Q1 Loss, Tops Revenue Estimates
Insmed (INSM) delivered earnings and revenue surprises of 2.20% and 1.09%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Insmed Reports First Quarter 2021 Financial Results and Provides Business Update
BRIDGEWATER, N.J., May 6, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today...
Analysts Estimate Insmed (INSM) to Report a Decline in Earnings: What to Look Out for
Insmed (INSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Insmed (INSM) Q1 Earnings Expected to Decline
Insmed (INSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.